Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWilmington Regulatory News (WIL)

Share Price Information for Wilmington (WIL)

Share Price is delayed by 15 minutes
Get Live Data
265.00    5.00 (1.92%)
Bid:
251.00
Ask:
259.00
Spread: 8.00 (3.187%)
Market Cap: £237.32m
WIL Live PriceLast checked at - London Stock Exchange

Intraday Wilmington Share Chart

Trading Statement

18 May 2017 07:00

RNS Number : 4771F
Wilmington PLC
18 May 2017
 

18 May 2017

 

Wilmington plc

Q3 Trading Update

 

Wilmington plc ("Wilmington" or "the business") the provider of information, education and networking services in Risk & Compliance, Professional, and Healthcare knowledge areas is today providing a trading update for the nine-month period to 31 March 2017.

 

Trading Update

Group revenue was up 13% (up 8% in constant currency) during the nine months ended 31 March 2017. Overall, revenue is in line with expectations, with good organic growth coming from our core growth areas of Risk & Compliance and the Healthcare businesses. Revenue growth was further supported by good contributions from the acquisitions made over the last two years and from the beneficial impact of currency translation. Offsetting this growth was, as previously reported, declines in some areas of the Professional division and the legacy charities and data suppression businesses.

During the nine-month period, Wilmington continued to see growth in reported operating profits, although this profit growth has been partially offset as reported in the interim results by continued investment across the business particularly in the US and in the compliance training areas where we see significant scope for stronger growth in the medium term.

 

Operational Review

Risk & Compliance 

Risk & Compliance again delivered strong revenue growth up 11% driven mainly by compliance training. In support of this growth and as reported in the interim results, we have continued to invest in new products, in the new North American operation and in additional support staff to expand our infrastructure and drive ICA membership. We have also been successful recently in winning two large international training programs which will benefit the business over the summer and we have brought in additional resources accordingly. This additional resource has further impacted margins in the short term but is expected to benefit contribution in 2017/18. Further investment continues to be made in our new North American compliance training business and in Compliance Week to expand its geographical reach in terms of events and information coverage.

Professional

Revenue was up 5% benefitting from favourable currency translation and the strong maiden performance from SWAT as well as our other accountancy training operations. However, the division continues to see the impact of the challenging conditions within the legal market as well as the impact of the weaker start to the financial year for AMT albeit we have recently regained stability in the Asia Pacific market.

The process for the planned disposal of Ark is underway and negotiations continue with potential buyers. Whilst Project Sixth Gear will provide benefits to the whole group, much of the work is centred around integrating the training businesses making up the bulk of the Professional division. This initiative is progressing well and we are attracting high calibre applicants for the divisional head role.

Healthcare 

Revenue was up 23% driven by organic growth across the board from our healthcare businesses and acquisitions made over the last two years. This was partially offset by continued declines in our legacy non-healthcare data suppression and charities businesses which make up around 20% of the division. HSJ, acquired on 31 January 2017 has also performed well and the HSJ team has been transferred to our Underwood Street premises. Integration is progressing on plan and is expected to be largely completed by the end of our 2016/17 financial year.

Cash Flow

Net debt as at 31 March 2017 was £51.4m (2016: £34.5m). This reflects strong cash generation and includes £20.3m paid in cash for two acquisitions made during the period. The Group has an overall borrowing facility of £85m which was extended from £65m in January 2017.

Adjusted measures

Effective from 30 June 2017 Wilmington will include share based payments costs within its definition of adjusted results. Share based payment costs amounted to £0.6m in 2015/16 and are not expected to be materially different during 2016/17.

Outlook

Wilmington continues to see the trends of tighter regulatory control and more complex legislation being implemented in most of our key markets, which in turn is driving demand for many of our products and services. We have and will continue to invest in our Compliance business to provide the infrastructure and support for anticipated future growth.

Despite the continued investment in infrastructure, the financial performance is in line with the Board's expectations and Wilmington is on track to deliver against expectations for the full year.

The information communicated in this announcement is inside information for the purposes of Article 7 of Market Abuse Regulation No. 596/2014

 

-End-

 

For further information, please contact:

Wilmington plc

Pedro Ros, Chief Executive Officer

Tony Foye, Chief Financial Officer

 

FTI Consulting

Charles Palmer / Emma Appleton / Adam Davidson

 

020 7422 6800

 

 

 

020 3727 1000

Notes to Editors

 

Wilmington plc is the recognised knowledge leader and partner of choice for information, education and networking in Risk & Compliance, Professional and Healthcare areas. Capitalised at approximately £210 million, Wilmington floated on the London Stock Exchange in 1995.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUBVNRBWAVAAR
Date   Source Headline
19th Mar 20184:18 pmRNSBoard Change - Correction
19th Mar 201811:34 amRNSHolding(s) in Company
16th Mar 20181:06 pmRNSBoard Change
15th Mar 20183:36 pmRNSHolding(s) in Company
2nd Mar 20182:13 pmRNSDirector/PDMR Shareholding
1st Mar 20189:00 amRNSVoting Rights and Capital
26th Feb 20188:34 amRNSDirector/PDMR Shareholding
22nd Feb 20183:49 pmRNSHolding(s) in Company
22nd Feb 20187:00 amRNSInterim Results
22nd Feb 20187:00 amRNSAppointment of Martin Morgan as Chairman
14th Feb 20182:50 pmRNSHolding(s) in Company
1st Feb 20189:10 amRNSHolding(s) in Company
1st Feb 20189:00 amRNSVoting Rights and Capital
4th Jan 20187:00 amRNSAcquisition of Interactive Medica
2nd Jan 20189:00 amRNSVoting Rights and Capital
18th Dec 20174:43 pmRNSNotification of Interim Results
1st Dec 20177:00 amRNSVoting Rights and Capital
29th Nov 20177:00 amRNSAppointment of new Chief Financial Officer
23rd Nov 201710:34 amRNSDirector/PDMR Shareholding
2nd Nov 20172:43 pmRNSResult of AGM
2nd Nov 20177:00 amRNSAGM and Q1 Trading Update
1st Nov 20179:12 amRNSVoting Rights and Capital
6th Oct 20175:58 pmRNSHolding(s) in Company
5th Oct 20173:45 pmRNSHolding(s) in Company
5th Oct 20173:44 pmRNSHolding(s) in Company
2nd Oct 20172:49 pmRNSVoting Rights and Capital
29th Sep 20179:27 amRNSDirector/PDMR Shareholding
27th Sep 20177:00 amRNSProposed Board Change
21st Sep 20171:47 pmRNSDirector/PDMR Shareholding
20th Sep 201711:50 amRNSShare Awards
18th Sep 20172:01 pmRNSVoting Rights and Capital
14th Sep 20172:48 pmRNSDirector/PDMR Shareholding
14th Sep 20179:33 amRNSDirector/PDMR Shareholding
13th Sep 20174:03 pmRNSDirector/PDMR Shareholding
13th Sep 20177:01 amRNSBoard Change
13th Sep 20177:00 amRNSFinal Results
22nd Aug 20171:52 pmRNSNotification of Final Results
18th Aug 20171:11 pmRNSHolding(s) in Company
1st Aug 201712:21 pmRNSVoting Rights and Capital
3rd Jul 20177:00 amRNSVoting Rights and Capital
28th Jun 20179:44 amRNSDirector/PDMR Shareholding
21st Jun 20173:05 pmRNSHolding(s) in Company
16th Jun 20174:35 pmRNSPrice Monitoring Extension
1st Jun 201712:00 pmRNSVoting Rights and Capital
19th May 201711:56 amRNSHolding(s) in Company
18th May 20177:00 amRNSTrading Statement
4th May 20177:00 amRNSProperty Disposal
3rd May 20171:56 pmRNSHolding(s) in Company
2nd May 20172:21 pmRNSVoting Rights and Capital
3rd Apr 201711:33 amRNSVoting Rights and Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.